Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor SB216763, in the Chronic Mild Stress Model of Mice
Figure 2
Effects of ketamine and the established GSK-3 inhibitor SB216763 in the CMS model.
(A) Locomotion: There were no differences between the four groups. Data show the mean±SEM (n = 8 or 9). (B) Tail-suspension test (TST): The increased immobility time of mice in the CMS groups, decreased significantly 48 hours (day 38) after a single dose of ketamine (10 mg/kg, i.p.), but not SB216763 (10 mg/kg, i.p.). Data show the mean±SEM (n = 5–8). (C) Forced swimming test (FST): The increased immobility time of mice in the CMS groups decreased significantly 48 hours (day 38) after a single dose of ketamine (10 mg/kg, i.p.), but not SB216763 (10 mg/kg, i.p.). Data show the mean±SEM (n = 8 or 9). *p<0.05, **p<0.01 as compared to CMS+Vehicle group.